Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma.
It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment.
Written by:
Khan KH, Fenton A, Murtagh E, McAleer JJ, Clayton A. Are you the author?
Drug Development Unit, Royal Marsden Hospital, Sutton, London, United Kingdom.
Reference: Tumori. 2012 Sep-Oct;98(5):139e-142e.
doi: 10.1700/1190.13216
PubMed Abstract
PMID: 23235770
UroToday.com Renal Cancer Section
